New treatment for mycosis fungoides or Sézary syndrome (SS)

Mogamulizumab licensed for the treatment of mycosis fungoides or Sézary syndrome (SS)

The European Commission has recently announced that mogamulizumab (brand name Poteligeo®) has been granted a licence for the treatment of adult patients with mycosis fungoides or Sézary syndrome who have received at least one previous systemic therapy.